- Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs<figure><div><img src="https://imgproxy.divecdn.com/Bdi5M4HMTn0nQ7Ww6DWMZBEaPY1McVmIyhbOSlOBYfo/g:nowe:0:194/c:1920:1085/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS8zODY4NjUwMzI1M…BioPharma Dive · 12d ago↗ source
- Draig nets $65M to advance depression drug aimed at rebuilding synapsesDraig Therapeutics has secured $65 million in an oversubscribed Series B raise to advance a pipeline of neuropsychiatry drugs, including its lead depression program designed to modulate the AMPA re…Endpoints · 12d ago↗ source
- Genetic medicine startup Lyora launches with programs from Editas, BiogenLyora Therapeutics will try to revive several early-stage genetic eye disease programs previously held by Editas Medicine and Biogen. The biotech was co-founded by Luk Vandenberghe and Eric Pie…